Related references
Note: Only part of the references are listed.Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
Steffen Dickopf et al.
BIOLOGICAL CHEMISTRY (2022)
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Anti-SARS-CoV-1 and-2 nanobody engineering towards avidity-inspired therapeutics
Eugene M. Obeng et al.
NANO TODAY (2022)
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
Antonio Tapia-Galisteo et al.
ONCOIMMUNOLOGY (2022)
Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide
Yu Du et al.
ANTI-CANCER DRUGS (2022)
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma
Zachery Halford et al.
ANNALS OF PHARMACOTHERAPY (2021)
Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies
Ivanna Hrynchak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Coiled coil-based therapeutics and drug delivery systems
Johanna Utterstrom et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
Mansour Poorebrahim et al.
CANCER GENE THERAPY (2021)
Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response
Raanan Greenman et al.
MOLECULAR CANCER THERAPEUTICS (2021)
FDA approves fourth CAR-T cell therapy
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Enrique J. Arenas et al.
NATURE COMMUNICATIONS (2021)
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
Ole A. Mandrup et al.
COMMUNICATIONS BIOLOGY (2021)
A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor
Michael Chen et al.
BIOMATERIALS SCIENCE (2021)
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Nawid Albinger et al.
GENE THERAPY (2021)
Engineering a cell-penetrating hyperstable antibody scFv(Ras)-An extraordinary approach to cancer therapeutics
Jina Bae et al.
SYNTHETIC AND SYSTEMS BIOTECHNOLOGY (2021)
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
Joseph H. Choe et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control
Roberta Lucchi et al.
ACS CENTRAL SCIENCE (2021)
Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning
Derek M. Mason et al.
NATURE BIOMEDICAL ENGINEERING (2021)
The role of XBP-1-mediated unfolded protein response in colorectal cancer progression-a regulatory mechanism associated with lncRNA-miRNA-mRNA network
Yong Wang et al.
CANCER CELL INTERNATIONAL (2021)
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Jean Lemoine et al.
CLINICAL CANCER RESEARCH (2021)
Highly accurate protein structure prediction with AlphaFold
John Jumper et al.
NATURE (2021)
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Jianjiang Fu et al.
ONCOGENE (2021)
Advancing to the era of cancer immunotherapy
Yun Wang et al.
CANCER COMMUNICATIONS (2021)
Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama
Igor E. Eliseev et al.
BIOMEDICINES (2021)
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
Fengzhen Mo et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization
Amir Sadeghi et al.
DRUG TESTING AND ANALYSIS (2020)
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours
Pieterjan Debie et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning
P. Gainza et al.
NATURE METHODS (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Katharina Reinhard et al.
SCIENCE (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
Tom A. Back et al.
EJNMMI RESEARCH (2020)
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah et al.
NATURE COMMUNICATIONS (2020)
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
Jiyeon Yun et al.
CANCER DISCOVERY (2020)
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
Janik Puttemans et al.
CANCERS (2020)
The immunogenicity of an anti-EGFR single domain antibody (VHH) is enhanced by misfolded amorphous aggregation but not by heat-induced aggregation
Md Golam Kibria et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
An intact C-terminal end of albumin is required for its long half-life in humans
Jeannette Nilsen et al.
COMMUNICATIONS BIOLOGY (2020)
Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
N. Girard et al.
ANNALS OF ONCOLOGY (2020)
CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
Mie K. Jakobsen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
Gils Roex et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis
Elmira Karami et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
Ab locks for improving the selectivity and safety of antibody drugs
Wen-Wei Lin et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Karin Staflin et al.
JCI INSIGHT (2020)
Comprehensive review of targeted therapy for colorectal cancer
Yuan-Hong Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Rakesh Awasthi et al.
BLOOD ADVANCES (2020)
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2019)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Engineering and Design of Chimeric Antigen Receptors
Sonia Guedan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
185PClinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients
V Van den bossche et al.
ANNALS OF ONCOLOGY (2019)
A coiled-coil masking domain for selective activation of therapeutic antibodies
Vivian H. Trang et al.
NATURE BIOTECHNOLOGY (2019)
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Yushu Joy Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Laurent Gauthier et al.
CELL (2019)
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
Katherine Griffiths et al.
MABS (2019)
Nanobody approval gives domain antibodies a boost
Chris Morrison
NATURE REVIEWS DRUG DISCOVERY (2019)
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Weilei Hu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Jesus Garcia-Foncillas et al.
FRONTIERS IN ONCOLOGY (2019)
Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial
Franck Morschhauser et al.
BLOOD (2019)
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
Irina V. Kholodenko et al.
MOLECULES (2019)
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Michael C. Burger et al.
FRONTIERS IN IMMUNOLOGY (2019)
Antibody interface prediction with 3D Zernike descriptors and SVM
Sebastian Daberdaku et al.
BIOINFORMATICS (2019)
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Zhipeng Su et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeting cancers through TCR-peptide/MHC interactions
Qinghua He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors
Andrey Krokhotin et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Sarah A. Richman et al.
CANCER IMMUNOLOGY RESEARCH (2018)
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
Renee C. G. de Bruin et al.
ONCOIMMUNOLOGY (2018)
Early Reconstitution of NK and gamma delta T Cells and Its Implication for the Design of Post-Transplant Immunotherapy
Moniek A. de Witte et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
Maren Knoedler et al.
BRITISH JOURNAL OF CANCER (2018)
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen et al.
CANCER CELL (2018)
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Tobias Speck et al.
CLINICAL CANCER RESEARCH (2018)
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Haitao Pan et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
Eric L. Smith et al.
MOLECULAR THERAPY (2018)
Haematological cancer: Blinatumomab facilitates complete responses
Diana Romero
Nature Reviews Clinical Oncology (2018)
The structural basis of nanobody unfolding reversibility and thermoresistance
Patrick Kunz et al.
SCIENTIFIC REPORTS (2018)
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
Shangjun Sun et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
Chunpeng Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface
Libin Zhang et al.
MACROMOLECULAR BIOSCIENCE (2018)
1497PJNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results
B C Cho et al.
ANNALS OF ONCOLOGY (2018)
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
Keisuke Watanabe et al.
FRONTIERS IN IMMUNOLOGY (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
Hiroshi Maeda et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
CD20-Tcb (RG6026), a Novel 2:1 Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial
Martin Hutchings et al.
BLOOD (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia
Sayed Shahabuddin Hoseini et al.
BLOOD ADVANCES (2018)
Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro
Ling Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability
Frederick W. Jacobsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
Katharine D. Grugan et al.
MABS (2017)
Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.
Diana Felice Hausman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeted cancer therapy through antibody fragments-decorated nanomedicines
Abbas Alibakhshi et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Driving better and safer HER2-specific CARs for cancer therapy
Xianqiang Liu et al.
ONCOTARGET (2017)
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
Dmitry Pankov et al.
ONCOTARGET (2017)
Structural basis of a novel heterodimeric Fc for bispecific antibody production
Hudie Wei et al.
ONCOTARGET (2017)
The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma
Christopher A. Schutt et al.
ONCOTARGET (2017)
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
Markus Granzin et al.
FRONTIERS IN IMMUNOLOGY (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA
D. Cunningham et al.
ANNALS OF ONCOLOGY (2017)
Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy
Ki-Hyun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Influence of molecular size on tissue distribution of antibody fragments
Zhe Li et al.
MABS (2016)
A review of blinatumomab, a novel immunotherapy
Matthew J. Newman et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Application of Coiled Coil Peptides in Liposomal Anticancer Drug Delivery Using a Zebrafish Xenograft Model
Jian Yang et al.
ACS NANO (2016)
Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity
Gorawit Yusakul et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Nanobodies as therapeutics: big opportunities for small antibodies
Sophie Steeland et al.
DRUG DISCOVERY TODAY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life
Ralph Adams et al.
MABS (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
18F-nanobody for PET imaging of HER2 overexpressing tumors
Catarina Xavier et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell
Maryam Qasemi et al.
PROTEIN EXPRESSION AND PURIFICATION (2016)
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
Juergen Borlak et al.
ONCOTARGET (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic NanobodyA® targeting the DR5 receptor
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Julia Stieglmaier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
A Novel 111In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
Kristell L. S. Chatalic et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Uwe Reusch et al.
MABS (2015)
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
Maarten Van Roy et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
Valentin Goede et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
Hans-Heinrich Oberg et al.
CANCER RESEARCH (2014)
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Heather A. Huet et al.
MABS (2014)
A general protocol for the generation of Nanobodies for structural biology
Els Pardon et al.
NATURE PROTOCOLS (2014)
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
Brian D. Harms et al.
METHODS (2014)
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
Omid Vafa et al.
METHODS (2014)
Recombinant expression and purification of human placental growth factor 1 and specific camel heavy chain polyclonal antibody preparation
Roghaye Arezumand et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2014)
Fusion protein linkers: Property, design and functionality
Xiaoying Chen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
Diana P. English et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
Shi Zhong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Oran Erster et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Maria J. W. D. Vosjan et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure
Vered Kunik et al.
NUCLEIC ACIDS RESEARCH (2012)
Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds
Gordana Wozniak-Knopp et al.
PLOS ONE (2012)
Reliable B Cell Epitope Predictions: Impacts of Method Development and Improved Benchmarking
Jens Vindahl Kringelum et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
Molecular mechanisms of Treg-mediated T cell suppression
Angelika Schmidt et al.
FRONTIERS IN IMMUNOLOGY (2012)
Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2011)
The Avastin Story
Mikkael A. Sekeres
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
HeR2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer
Fortunato Ciardiello et al.
CANCER DISCOVERY (2011)
Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
S. R. Yoon et al.
BONE MARROW TRANSPLANTATION (2010)
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Antibody fragments Hope and hype
Aaron L. Nelson
MABS (2010)
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Sonja Loges et al.
CANCER CELL (2009)
Development trends for therapeutic antibody fragments
Aaron L. Nelson et al.
NATURE BIOTECHNOLOGY (2009)
Glycosylation as a strategy to improve antibody-based therapeutics
Roy Jefferis
NATURE REVIEWS DRUG DISCOVERY (2009)
Bioinformatics construction of the human cell surfaceome
J. P. C. da Cunha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Camelid immunoglobulins and nanobody technology
S. Muyldermans et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2009)
Engineering peptide linkers for scFv immunosensors
Zhihong Shen et al.
ANALYTICAL CHEMISTRY (2008)
PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure
Michael J. Sweredoski et al.
BIOINFORMATICS (2008)
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction
Fabio Turatti et al.
JOURNAL OF IMMUNOTHERAPY (2007)
CD8+ T cell activation is governed by TCR-Peptide/MHC affinity, not dissociation rate
Shaomin Tian et al.
JOURNAL OF IMMUNOLOGY (2007)
Targeting HER proteins in cancer therapy and the role of the non-target HER3
A. C. Hsieh et al.
BRITISH JOURNAL OF CANCER (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
E De Genst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Pentamerization of single-domain antibodies from phage libraries: A novel strategy for the rapid generation of high-avidity antibody reagents
JB Zhang et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Human T regulatory cells can use the perforin pathway to cause autologous target cell death
WJ Grossman et al.
IMMUNITY (2004)
Share Paper
